[{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Tenmile","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"LGR5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carina Biotech \/ Tenmile","highestDevelopmentStatusID":"5","companyTruncated":"Carina Biotech \/ Tenmile"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Carina Biotech \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Carina Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : CNA3103 is a LGR5-targeted CAR-T cell therapy candidate which is being evaluated in phase 1/2 clinical trials for the treatment of adult patients with metastatic colorectal cancer (mCRC).

                          Product Name : CNA3103

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          December 18, 2023

                          Lead Product(s) : CNA3103

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : CNA3103 is a LGR5 targeted CAR-T cells have potential to be developed as a novel immunotherapy to kill ovarian cancer cells and to reduce ovarian cancer tumor.

                          Product Name : CNA3103

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          June 02, 2023

                          Lead Product(s) : CNA3103

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : CNA3103 CAR-T cell targets LGR5, a cancer stem cell marker that is highly expressed on advanced colorectal cancer and some other cancers. CNA3103 have shown promising results with complete tumor regression and no tumor recurrence following a single admin...

                          Product Name : CNA3103

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          January 24, 2023

                          Lead Product(s) : CNA3103

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Carina’s CAR-T cell therapy candidate, CNA3103, is targeted at LGR5, a cancer stem cell marker that is highly expressed on advanced colorectal cancer and some other cancers.

                          Product Name : CNA3103

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          December 12, 2022

                          Lead Product(s) : CNA3103

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The capital raise enables Carina to complete its Investigational New Drug (IND) enabling studies and initiate a CAR-T clinical trial of LGR5 CAR-T cell for patients with advanced colorectal (bowel) cancer.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 18, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Tenmile

                          Deal Size : $7.5 million

                          Deal Type : Financing

                          blank